IMATINIB

Brand name:

• Imatab

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Juno Pharmaceuticals Pty Ltd

Condition/indication:
(therapeutic use)

• Chronic myeloid leukaemia (CML); Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL); Myelodysplastic or myeloproliferative disorder (MDS/MPD); Aggressive systemic mastocytosis (ASM) with eosinophilia; Chronic eosinophilic leukaemia (CEL) or Hypereosinophilic syndrome (HES); Dermatofibrosarcoma protuberans (DFSP); Gastrointestinal stromal tumour (GIST); Malignant GIST.

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (–)

Comment:

--

Other PBAC consideration:

--

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

13/12/2021

Lodgement of required documentation:

23/12/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 11/01/2022

Status:

Finalised

Government processes:

Commenced on 18/01/2022

Medicine listed on the PBS:

01/04/2022 (see PBS schedule)